Human Stem Cells Institute Past Earnings Performance
Past criteria checks 1/6
Human Stem Cells Institute has been growing earnings at an average annual rate of 50%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 20.5% per year. Human Stem Cells Institute's return on equity is 7.7%, and it has net margins of 1.5%.
Key information
50.0%
Earnings growth rate
49.8%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 20.5% |
| Return on equity | 7.7% |
| Net Margin | 1.5% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Human Stem Cells Institute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1,144 | 17 | 502 | 0 |
| 31 Mar 22 | 1,162 | 14 | 499 | 0 |
| 31 Dec 21 | 1,181 | 12 | 497 | 0 |
| 30 Sep 21 | 1,184 | 16 | 471 | 0 |
| 30 Jun 21 | 1,188 | 20 | 443 | 0 |
| 31 Mar 21 | 1,136 | 46 | 427 | 0 |
| 31 Dec 20 | 1,084 | 73 | 411 | 0 |
| 30 Sep 20 | 994 | 89 | 394 | 0 |
| 30 Jun 20 | 904 | 106 | 377 | 0 |
| 31 Mar 20 | 870 | 95 | 377 | 0 |
| 31 Dec 19 | 836 | 85 | 377 | 0 |
| 30 Sep 19 | 786 | 34 | 369 | 0 |
| 30 Jun 19 | 736 | -16 | 360 | 0 |
| 31 Mar 19 | 691 | -25 | 355 | 0 |
| 31 Dec 18 | 645 | -34 | 351 | 0 |
| 30 Sep 18 | 611 | -84 | 363 | 0 |
| 30 Jun 18 | 561 | -25 | 371 | 0 |
| 31 Mar 18 | 526 | -66 | 370 | 0 |
| 31 Dec 17 | 494 | -103 | 371 | 0 |
| 30 Sep 17 | 457 | -26 | 383 | 0 |
| 30 Jun 17 | 428 | -92 | 379 | 0 |
| 31 Mar 17 | 412 | -124 | 372 | 0 |
| 31 Dec 16 | 390 | -111 | 337 | 0 |
| 30 Sep 16 | 365 | -139 | 303 | 0 |
| 30 Jun 16 | 348 | -131 | 287 | 0 |
| 31 Mar 16 | 328 | -67 | 253 | 0 |
| 31 Dec 15 | 311 | -52 | 243 | 0 |
Quality Earnings: ISKJ has a large one-off loss of RUB14.8M impacting its last 12 months of financial results to 30th June, 2022.
Growing Profit Margin: ISKJ's current net profit margins (1.5%) are lower than last year (1.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISKJ has become profitable over the past 5 years, growing earnings by 50% per year.
Accelerating Growth: ISKJ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ISKJ had negative earnings growth (-15.9%) over the past year, making it difficult to compare to the Biotechs industry average (-26.8%).
Return on Equity
High ROE: ISKJ's Return on Equity (7.7%) is considered low.